Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Incruse Ellipta
Umeclidinium is a long-acting muscarinic antagonist (LAMA) used in the management of chronic obstructive pulmonary disease (COPD). It works by blocking the action of acetylcholine at muscarinic receptors in the lungs, leading to bronchodilation and improved airflow.
For maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema.
Outcome:
Increased umeclidinium exposure
Mechanism:
Reduced umeclidinium metabolism
Outcome:
Potential for hypokalemia
Mechanism:
Additive effects on potassium excretion
Outcome:
Potential for reduced umeclidinium absorption
Mechanism:
Binding of umeclidinium in the GI tract
Most likely new formulation: A combined inhaler with a long-acting beta-agonist and inhaled corticosteroid (2025, 75% confidence)
Based on current usage trends and clinical trial data, there is a 90% likelihood that umeclidinium will maintain its approved status for COPD treatment in the next 5 years.
Muscarinic Antagonist, Bronchodilator
Quinuclidine Derivative